These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

45 related articles for article (PubMed ID: 24767354)

  • 1. Correlation between mycophenolic acid blood level and renal dysfunction in stable liver transplant recipients receiving mycophenolate monotherapy.
    Park YH; Hwang S; Song GW; Jung DH; Ahn CS; Kim KH; Moon DB; Ha TY; Park GC; Kim N; Lee SG
    Transplant Proc; 2014 Apr; 46(3):811-5. PubMed ID: 24767354
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Limited sampling model for advanced mycophenolic acid therapeutic drug monitoring after liver transplantation.
    Langers P; Press RR; Inderson A; Cremers SC; den Hartigh J; Baranski AG; van Hoek B
    Ther Drug Monit; 2014 Apr; 36(2):141-7. PubMed ID: 24081208
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A comparison of measured trough levels and abbreviated AUC estimation by limited sampling strategies for monitoring mycophenolic acid exposure in stable heart transplant patients receiving cyclosporin A-containing and cyclosporin A-free immunosuppressive regimens.
    Dösch AO; Ehlermann P; Koch A; Remppis A; Katus HA; Dengler TJ
    Clin Ther; 2006 Jun; 28(6):893-905. PubMed ID: 16860172
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of mycophenolic acid pharmacokinetic parameters in kidney transplant patients within the first 3 months post-transplant.
    Pawinski T; Durlik M; Szlaska I; Urbanowicz A; Majchrnak J; Gralak B
    J Clin Pharm Ther; 2006 Feb; 31(1):27-34. PubMed ID: 16476117
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A clinical assessment of mycophenolate drug monitoring after liver transplantation.
    Hwang S; Lee SG; Ahn CS; Kim KH; Moon DB; Ha TY; Song GW; Jung DH; Choi NK; Kim KW; Yu YD; Park GC; Park PJ; Choi YI
    Clin Transplant; 2010; 24(2):E35-42. PubMed ID: 20070319
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mycophenolate mofetil monotherapy in patients who underwent liver transplantation for hepatitis C cirrhosis.
    Manrique A; Jiménez C; Ortega P; Abradelo M; Gimeno A; Calvo J; Cambra F; -Sterup RL; Morales JM; Moreno E
    Transplant Proc; 2008 Nov; 40(9):2962-4. PubMed ID: 19010160
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mycophenolic acid trough level monitoring in solid organ transplant recipients treated with mycophenolate mofetil: association with clinical outcome.
    Kaplan B
    Curr Med Res Opin; 2006 Dec; 22(12):2355-64. PubMed ID: 17257450
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of mycophenolate mofetil on erythropoiesis in stable renal transplant patients is correlated with mycophenolic acid trough levels.
    van Besouw NM; van der Mast BJ; Smak Gregoor PJ; Hesse CJ; IJzermans JN; van Gelder T; Weimar W
    Nephrol Dial Transplant; 1999 Nov; 14(11):2710-3. PubMed ID: 10534517
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pediatric aspects of therapeutic drug monitoring of mycophenolic acid in renal transplantation.
    Tönshoff B; David-Neto E; Ettenger R; Filler G; van Gelder T; Goebel J; Kuypers DR; Tsai E; Vinks AA; Weber LT; Zimmerhackl LB
    Transplant Rev (Orlando); 2011 Apr; 25(2):78-89. PubMed ID: 21454065
    [TBL] [Abstract][Full Text] [Related]  

  • 10. AcylMPAG plasma concentrations and mycophenolic acid-related side effects in patients undergoing renal transplantation are not related to the UGT2B7-840G>A gene polymorphism.
    van Agteren M; Armstrong VW; van Schaik RH; de Fijter H; Hartmann A; Zeier M; Budde K; Kuypers D; Pisarski P; Le Meur Y; van der Werf M; Mamelok RD; Oellerich M; van Gelder T
    Ther Drug Monit; 2008 Aug; 30(4):439-44. PubMed ID: 18641546
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Serum Trough Concentration and Effects of Mycophenolate Mofetil Based on Pathologic Findings in Infants After Liver Transplantation.
    Ueno T; Kodama T; Noguchi Y; Deguchi K; Nomura M; Saka R; Watanabe M; Tazuke Y; Bessho K; Okuyama H
    Transplant Proc; 2020; 52(6):1855-1857. PubMed ID: 32571709
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of pharmacokinetics of mycophenolic acid and its glucuronide between patients with lupus nephritis and with kidney transplantation.
    Mino Y; Naito T; Matsushita T; Otsuka A; Ushiyama T; Ozono S; Hishida A; Kagawa Y; Kawakami J
    Ther Drug Monit; 2008 Dec; 30(6):656-61. PubMed ID: 18978521
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Therapeutic dose monitoring of mycophenolate mofetil in dermatologic diseases.
    Sokumbi O; el-Azhary RA; Langman LJ
    J Am Acad Dermatol; 2013 Jan; 68(1):36-40. PubMed ID: 22884445
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mycophenolate blood level monitoring: recent progress.
    van Gelder T
    Am J Transplant; 2009 Jul; 9(7):1495-9. PubMed ID: 19519824
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Intra-individual variability of mycophenolic acid concentration according to renal function in liver transplant recipients receiving mycophenolate monotherapy.
    Hwang S; Song GW; Jung DH; Park GC; Ahn CS; Moon DB; Ha TY; Kim KH; Lee SG
    Ann Hepatobiliary Pancreat Surg; 2017 Feb; 21(1):11-16. PubMed ID: 28317040
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Monitoring trough plasma concentrations of mycophenolate mofetil in patients with uveitis.
    Llinares-Tello F; Hernández-Prats C; Muñoz-Ruiz C; Selva-Otaolaurruchi J; Ordovás-Baines JP
    J Clin Pharm Ther; 2004 Feb; 29(1):53-8. PubMed ID: 14748898
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Therapeutic drug monitoring of total and free mycophenolic acid (MPA) and limited sampling strategy for determination of MPA-AUC in paediatric renal transplant recipients. The German Study Group on Mycophenolate Mofetil (MMF) Therapy.
    Weber LT; Schütz E; Lamersdorf T; Shipkova M; Niedmann PD; Oellerich M; Zimmerhackl LB; Staskewitz A; Mehls O; Armstrong VW; Tönshoff B
    Nephrol Dial Transplant; 1999; 14 Suppl 4():34-5. PubMed ID: 10463209
    [No Abstract]   [Full Text] [Related]  

  • 18. Significance of mycophenolate monitoring in liver transplant recipients: toward the cut-off level.
    Sarvary E; Nemes B; Varga M; Gaal I; Monostory K; Langer RM; Gorog D; Fazakas J; Kobori L; Fehervari I; Gerlei Z
    Transplant Proc; 2012 Sep; 44(7):2157-61. PubMed ID: 22974941
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Real life experience of mycophenolate mofetil monotherapy in liver transplant patients.
    Lassailly G; Dumortier J; Saint-Marcoux F; El Amrani M; Boulanger J; Boleslawski E; Millet G; Ningarhari M; Truant S; Canva V; Goria O; Boillot O; Louvet A; Mathurin P; Lebuffe G; Pruvot FR; Marquet P; Dharancy S
    Clin Res Hepatol Gastroenterol; 2021 Jan; 45(1):101451. PubMed ID: 32536555
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Use of Glucuronidated Mycophenolic Acid Levels for Therapeutic Monitoring in Pediatric Lupus Nephritis Patients.
    Hui-Yuen JS; Tran T; Taylor J; Truong K; Li X; Bermudez LM; Starr AJ; Eichenfield AH; Imundo LF; Askanase AD
    J Clin Rheumatol; 2016 Mar; 22(2):75-9. PubMed ID: 26906299
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 3.